Claims Scope:

Patent issued July 31, 2018. 

≥80% Sequence Identity – Compositions only 

Compositions of viral vectors for treating a condition associated with the mevalonate pathway comprising shRNA or miRNA capable of inhibiting the mevalonate pathway with shRNA having at least 80% percent identity to SEQ 1-4, or, microRNA having at least 80% identity to SEQ 5-10. 

No limitation to activating GD T cells or infecting cancer cells.